El-Khoueiry, MD, an associate professor of clinical medicine in the Division of Medical Oncology and director of the phase I ...

The FDA has approved belantamabmafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd), as well ...

The US FDA has granted fast track designation to the novel amanitin-based antibody-drug conjugate (ADC) pamlectabart ...

Patel discusses the design and patient criteria for the pivotal C-POST trial evaluating adjuvant cemiplimab in high-risk ...

Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.

Iams, MD, MSCI, examined outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer. Adding immunotherapy to platinum-based chemotherapy is an established standard of care for ...

Camu camu, containing castalagin, was safe in combination with immune checkpoint inhibitors for melanoma and NSCLC patients, with manageable adverse events. The melanoma cohort showed a 13% ORR in ...

The CALYPSO trial showed no improvement in outcomes with savolitinib addition in advanced ccRCC patients previously treated with VEGF-targeted therapy. ORRs were 10% for durvalumab, 28% for durvalumab ...

Bradley Monk, MD, highlights transformative long-term outcomes from the innovaTV trial, showcasing innovative treatments for cervical cancer at ESMO 2025. Bradley Monk, MD, discusses the long-term ...

Sapanisertib combined with weekly paclitaxel improved PFS in platinum-resistant ovarian cancer, reducing the risk of death by 34% compared to paclitaxel alone. The combination therapy was generally ...

Alternative donors, including mismatched unrelated and haploidentical related donors, offer similar transplant success as fully matched donors for hematologic malignancies. The study supports avoiding ...

During a live event, Lori Wirth, MD, discussed next steps for treating a patient with progressive, radioactive ...